Search - tctmd.com

Displaying 21 - 40 of 124

Sort: Relevancy | Date

Presentation TCT 2023

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

Presenter: David Kandzari

October 25, 2023

Presentation TCT 2023

SYMAP Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

TCT 53: Every Third Patient with Advanced Renal Failure Dies Within One Year Following Non ST-Segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention

Presenter: Rafal Januszek

October 25, 2023

Presentation TCT 2023

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: David Kandzari

October 25, 2023

Presentation TCT 2023

RADIANCE Clinical Trial Program (Ultrasound Renal Denervation)

Presenter: Ajay Kirtane

October 25, 2023

Presentation TCT 2023

Preclinical Science In Renal Denervation – What Is New, What Is Clinically Relevant?

Presenter: Lucas Lauder

October 25, 2023

Presentation TCT 2023

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

Presenter: Michael Bloch

October 25, 2023

Presentation TCT 2023

TCT 697: Impact of Coronary Atherosclerotic Burden on the Long-Term Prognosis of Patients With Chronic Kidney Disease Undergoing Renal Replacement Therapy

Presenter: Roger Godinho

October 25, 2023

Presentation TCT 2023

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

Presenter: Ron miller

October 25, 2023

Presentation TCT 2023

TCT 640: Trends in Patients With and Without End Stage Renal Disease Undergoing Transcatheter Edge-To-Edge Mitral Valve Repair

Presenter: Ufuk Vardar

October 25, 2023

Presentation TCT 2023

TCT 3: Renal Artery Denervation Combined with Pulmonary Vein Isolation in Patients with Heart Failure and Atrial Fibrillation - Pilot Study

Presenter: Tomasz Skowerski

October 25, 2023

Presentation TCT 2023

TCT 228: Three-year outcomes between patients with acute myocardial infarction, with and without obstructive coronary artery disease, according to renal function

Presenter: Yong Hoon Kim

October 25, 2023

Presentation TCT 2023

TCT 946: Mechanical Thrombectomy of a Cavoatrial Tumor Thrombi Using the AlphaVac System in Renal Cell Carcinoma

Presenter: Akruti Prabhakar

October 25, 2023

Presentation TCT 2023

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

Presenter: Hamza Naveed

October 25, 2023

Presentation TCT 2023

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Michel Azizi

October 25, 2023

Presentation TCT 2023

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

Presenter: Victor Zeijen

October 25, 2023

Presentation TCT 2023

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

Presenter: Karl Fengler

October 25, 2023

Presentation TCT 2023

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Presenter: Anna Subbotina

October 25, 2023

Presentation TCT 2023

Are Outcome Trials Necessary for Renal Denervation Therapies?

Presenter: Ajay Kirtane

October 24, 2023

Advertisement

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

SYMAP Clinical Trial Program (Radio-Frequency Renal Denervation)

TCT 53: Every Third Patient with Advanced Renal Failure Dies Within One Year Following Non ST-Segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

RADIANCE Clinical Trial Program (Ultrasound Renal Denervation)

Preclinical Science In Renal Denervation – What Is New, What Is Clinically Relevant?

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

TCT 697: Impact of Coronary Atherosclerotic Burden on the Long-Term Prognosis of Patients With Chronic Kidney Disease Undergoing Renal Replacement Therapy

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

TCT 640: Trends in Patients With and Without End Stage Renal Disease Undergoing Transcatheter Edge-To-Edge Mitral Valve Repair

TCT 3: Renal Artery Denervation Combined with Pulmonary Vein Isolation in Patients with Heart Failure and Atrial Fibrillation - Pilot Study

TCT 228: Three-year outcomes between patients with acute myocardial infarction, with and without obstructive coronary artery disease, according to renal function

TCT 946: Mechanical Thrombectomy of a Cavoatrial Tumor Thrombi Using the AlphaVac System in Renal Cell Carcinoma

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Are Outcome Trials Necessary for Renal Denervation Therapies?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content